FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS: Leaving the study early
- Population
- patients with schizophrenia
- Intervention
- FLUPHENAZINE DECANOATE
- Comparison
- ORAL NEUROLEPTICS
- Outcome
- Leaving the study early
FLUPHENAZINE DECANOATE showed no clear difference in leaving the study early compared with ORAL NEUROLEPTICS (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS Leaving the study early · patients with schizophrenia FLUPHENAZINE DECANOATE showed no clear difference in leaving the study early compared with ORAL NEUROLEPTICS (low certainty). Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane Headline outcomes only | RR 0.96 [0.73, 1.25] | 10 studies · 937 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Fluphenazine decanoate (depot) and enanthate for schizophrenia 2015 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- FLUPHENAZINE DECANOATE vs placebo · patients with schizophrenia · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.